Liraglutide is a subcutaneous injection (approved in Egypt for treating T2DM), a human glucagon-like peptide 1 (GLP-1) with an established plasma glucose-lowering effect, thus reducing the risk of microvascular complications [3]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.